26 results about "Deficiency syndrome" patented technology

The invention belongs to the field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating liver depression and spleen deficiency syndrome metabolism-related fatty liver disease, which is prepared from the following raw materials in parts by weight: 8 to 10 parts of ginseng, 10 to 15 parts of radix bupleuri, 10 to 15 parts of radix curcumae, 6 to 9 parts of ginger processed pinellia, 6 to 10 parts of fructus amomi, 10 to 15 parts of rhizoma atractylodis, 10 to 15 parts of poria cocos, 10 to 15 parts of semen hoveniae, 10 to 15 parts of radix rehmanniae, 8 to 10 parts of rhizoma polygoni cuspidati and 6 to 9 parts of lignum dalbergiae odoriferae. The traditional Chinese medicine composition is used for treating the metabolism-related fatty liver diseases from the aspects of liver depression, spleen deficiency and phlegm-blood stasis, starts from the core pathological chain of liver depression, spleen deficiency, phlegm-dampness and blood stasis, has the functions of soothing the liver, tonifying the spleen, resolving dampness, reducing fat and promoting blood circulation to remove meridian obstruction, and is particularly suitable for patients with liver depression, spleen deficiency and metabolism-related fatty liver diseases. Clinical tests prove that the traditional Chinese medicine composition has a good treatment effect on patients with liver depression and spleen deficiency syndrome metabolism-related fatty liver diseases, the total effective rate reaches 94% or above, and the traditional Chinese medicine composition is mild in medicine property, good in safety, stable in curative effect, not prone to relapse and suitable for being taken for a long time.

The invention relates to the technical field of disease animal models, in particular to a construction method, an evaluation method and application of a bipolar affective disorder liver stagnation and spleen deficiency syndrome combined animal model. According to the method, a liver depression and spleen deficiency syndrome modeling method is adopted for model construction, evaluation indexes are formulated by combining manic and depression behavior expressions of mice and innovatively combining typical expressions of liver depression and spleen deficiency, a liver depression and spleen deficiency syndrome animal model evaluation method is explored, and a thought is provided for achieving standardization and normalization of liver depression and spleen deficiency syndrome model evaluation. The modeling method is simple and economical, provides an experimental animal model for syndrome differentiation treatment of diseases, particularly provides a corresponding animal model for traditional Chinese medicine syndrome differentiation treatment and new drug pharmacological experiments, accelerates the progress of traditional Chinese medicine disease syndrome research and new drug development, provides technical service for drug evaluation, and has great application value.

The invention relates to the field of medical health monitoring, and provides a spleen and kidney deficiency syndrome dynamic evaluation system based on a multi-modal biosensor, which comprises a wearable device, and is characterized in that a multi-modal biosensing assembly and an ARM evaluation processor are arranged in the wearable device; the multi-modal biosensing assembly forms a first evaluation table based on sensing difference data of multi-modal sensing data in different acquisition stages within the wearing time of a user; wherein the first evaluation table is used for performing primary and secondary sensing signal scoring on the user according to the sensing difference value data; and the ARM processor is used for constructing a preset spleen and kidney deficiency evaluation model according to the primary and secondary induction scoring signals, and dynamically outputting visual spleen and kidney evaluation information of the user according to the spleen and kidney deficiency evaluation model.

This invention relates to the treatment of glucose transporter type 1 deficiency syndrome (Glut1-DS). In particular, the invention relates to specific medium-chain triglyceride compositions, enriched for C10 (decanoic acid), for use in treating movement disorders in Glut1-DS patients.

The invention discloses a medicinal and edible traditional Chinese medicine composition for postoperative rehabilitation as well as a preparation method and application of the medicinal and edible traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 12 to 27 parts of radix astragali seu hedysari, 2 to 10 parts of radix ginseng, 2 to 10 parts of colla corii asini, 5 to 18 parts of radix angelicae sinensis, 8 to 25 parts of cortex eucommiae, 5 to 18 parts of semen persicae, 23 to 37 parts of small red beans, 8 to 25 parts of pericarpium citri reticulatae, 23 to 37 parts of fructus ziziphi jujubae, 2 to 10 parts of rhizoma zingiberis recens and 8 to 25 parts of semen ziziphi spinosae. The traditional Chinese medicine composition has the effects of tonifying qi and nourishing blood, promoting blood circulation to remove blood stasis and strengthening the spleen and stomach, integrates the effects of tonifying qi and nourishing blood, warming and dredging to remove blood stasis and strengthening the spleen and soothing the nerves in one formula, can cover common deficiency syndrome types, and breaks through the limitation of traditional Chinese medicine individualized dialectical treatment in popularization.

The invention discloses a kidney essence deficiency diagnosis model construction and optimization construction method and system, and the method comprises the steps: carrying out the grouping processing of basic clinical information data, and obtaining the baseline data of kidney essence deficiency syndromes; performing standard equalization processing on the kidney essence deficiency syndrome baseline data to obtain kidney essence deficiency syndrome standard data, performing grouping analysis on the kidney essence deficiency syndrome standard data to generate an optimal model training set, and calculating and determining a kidney essence deficiency syndrome score of each group of kidney essence deficiency syndrome standard data after grouping; according to a diagnosis model structure, the kidney essence deficiency syndrome score and the quantification interval of the kidney essence deficiency syndrome score, constructing an initial kidney essence deficiency diagnosis model; and training the initial kidney essence deficiency diagnosis model based on each group of kidney essence deficiency syndrome standard data and the optimal model training set, and obtaining an optimal kidney essence deficiency diagnosis model according to a training result. By applying the method and the system provided by the invention, the diagnosis and prediction level and accuracy of the kidney essence deficiency syndrome are improved.

The invention provides a false symptom patient tongue picture recognition method based on a two-stage graph convolution Mama network, and the method comprises the steps: carrying out the superpixel segmentation of a tongue picture image through employing an SLIC algorithm, and dividing the tongue picture image into B sub-graphs; local aggregation and enhancement of spectral and spatial features in sub-graphs are carried out through a two-stage graph convolution layer and a DSFR module, and an enhanced node feature matrix is obtained; obtaining absolute position information of each sub-graph through an RAPE module, and fusing the absolute position information with the enhanced node feature matrix to obtain a feature embedding sequence of the sub-graphs; performing global spatial feature learning based on a Mama network by taking the feature embedding sequence of the sub-graph as input to obtain a model output feature graph; and performing category mapping on the tongue picture category through MLP to obtain a tongue picture recognition result. According to the method, the classification precision in a complex environment is improved, and the problems of high calculation complexity and information redundancy of a multi-branch model are avoided.

The present invention relates to a novel antisense transcript to the human SLC2A1 (Glut1) gene, variants and fragments thereof. This antisense transcript can be used to modulate Glut1 expression and serve to restore Glut1, and as a therapeutic for treating or preventing Glut 1 deficiency syndrome, or other Glut1 related conditions including certain cancers, diabetes, Alzheimer's disease, and retinitis pigmentosa.

The present application relates to the technical field of medicine, and especially relates to a combined Chinese and western medicine composition and application thereof, wherein the combined Chinese and western medicine composition comprises Chinese patent medicine and western medicine; the raw material of the Chinese patent medicine comprises Strychnos seed powder, Earthworm, Codonopsis, Poria cocos, Atractylodes, Chuanxiong, Salvia miltiorrhiza, Panax notoginseng, Radix et Rhizoma Bovis, and Radix Glycyrrhizae; and the effective component of the western medicine is diclofenac; the application of the combined Chinese and western medicine composition in preparation of a lumbar pain medicine; the application is for preparation of intervertebral disc-derived lumbar pain medicines of different syndromes; the syndrome is preferably qi and blood deficiency syndrome; the combined Chinese and western medicine composition can effectively treat intervertebral disc-derived lumbar pain of different syndromes through mutual cooperation between the Chinese patent medicine and the western medicine, and the curative effect is more obvious for intervertebral disc-derived lumbar pain of qi and blood deficiency syndrome.

This invention relates to the treatment of glucose transporter type 1 deficiency syndrome (Glut1-DS). In particular, the invention relates to specific medium-chain triglyceride compositions, enriched for C10 (decanoic acid), for use in treating movement disorders in Glut1-DS patients.

The present invention relates to compositions comprising a methyl group donor compound and an acetyl-CoA donor compound for use in therapy and prevention of diseases associated with dysfunction of mitochondriae, wherein the diseases associated with dysfunction of mitochondriae are nucleotide excision repair deficiency syndromes, especially Xeroderma pigmentosum A, or DNA repair deficiency syndrome ataxia telangiectasia associated with mitochondrial dysfunction. Particularly, the composition is used for therapy of nucleotide excision repair deficiency syndromes, such as Xeroderma pigmentosum A, B, C, D, E, F, G, V, the different forms of Cockayne syndrome (CS), such as Cockayne syndrome type B (CSB) and Cockayne syndrome type A (CSA), and trichothiodystrophy (TTD), or DNA repair deficiency syndrome ataxia telangiectasia associated with mitochondrial dysfunction.

Use of digestive aid tablets in the preparation of a drug for treating irritable bowel syndrome. The digestive aid tablets consist of Citri Reticulatae Pericarpium, Pseudostellariae Radix, stir-fried Hordei Fructus Germinatus, Crataegi Fructus, and Dioscoreae Rhizoma, and exhibit significant efficacy in the treatment of irritable bowel syndrome with diarrhea and liver qi stagnation and spleen deficiency syndrome.

The application provides a method for screening active ingredients capable of activating TAS1R3 receptors, and belongs to the technical field of screening of active ingredients of traditional Chinese medicines. The application establishes a biosensor, and the biosensor detects the current signal after each concentration of compound solution reacts with the TAS1R3 receptor; the dissociation constant K D of the interaction between the compound and the TAS1R3 receptor is calculated according to the linear fitting equation between the common logarithm of the concentration of the compound and the current change, and the compound with the K D value in the range of 10 ‑13 -10 ‑8 M is screened as the active ingredient capable of activating the TAS1R3 receptor. In the application, the interaction dissociation constant K D of the Atractylodes lactone II and the glycyrrhizic acid with the TAS1R3 protein is 3.759*10 ‑8 M and 4.435*10 ‑9 M respectively, and the binding force with the TAS1R3 protein is very strong. Moreover, the Atractylodes lactone II and the glycyrrhizic acid have the function of improving anemia within a certain concentration, and provide a new idea for the screening of candidate compounds with the sweet characteristic and the treatment of anemia or blood deficiency syndrome in traditional Chinese medicines and the research and development of new drugs.

This invention provides a method for establishing a rat model of COPD to study the medicinal uses and pharmacological effects of Liuwei Buqi Decoction in the treatment of COPD. The traditional Chinese medicines in Liuwei Buqi Decoction are ginseng, astragalus, alpinia oxyphylla, polygonatum odoratum, tangerine peel, and cinnamon. This application provides a basis for the syndrome differentiation and treatment strategy of Liuwei Buqi Decoction by exploring the molecular mechanisms by which Liuwei Buqi Decoction regulates the COPD inflammatory immune network and the molecular mechanisms by which it regulates the lung-gut microecological axis and the inflammatory immune network. Taking the high-incidence syndromes of major diseases during the TCM-advantage stage as a starting point, and based on clinical needs, this study, building upon previous clinical research, uses various techniques such as scRNA-seq, CBA, and metagenomics to explore the molecular mechanism by which Liuwei Buqi Decoction improves airway immune inflammation by regulating the lung microecology in rats with COPD lung-kidney qi deficiency syndrome from the perspective of regulating the lung immune microenvironment and alveolar macrophage polarization. Its mechanism of action was further studied and verified through in vitro experiments.

The application belongs to the field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating metabolic-related fatty liver disease of liver stagnation and spleen deficiency syndrome, which is composed of the following raw materials by weight: 8-10 parts of ginseng, 10-15 parts of bupleurum, 10-15 parts of curcuma zedoary, 6-9 parts of pinellia, 6-10 parts of amomum, 10-15 parts of atractylodes, 10-15 parts of poria, 10-15 parts of hovenia dulcis, 10-15 parts of rehmannia, 8-10 parts of giant knotweed, and 6-9 parts of olibanum. The traditional Chinese medicine composition treats metabolic-related fatty liver disease from the perspective of liver stagnation and spleen deficiency and phlegm and blood stasis, and starts from the core pathological chain of liver stagnation, spleen deficiency, phlegm and blood stasis, and has the functions of soothing liver and strengthening spleen, removing dampness and fat, and activating blood and dredging collaterals. The traditional Chinese medicine composition is especially suitable for patients with metabolic-related fatty liver disease of liver stagnation and spleen deficiency syndrome. Clinical tests prove that the traditional Chinese medicine composition has good therapeutic effect on patients with metabolic-related fatty liver disease of liver stagnation and spleen deficiency syndrome, and the total effective rate is more than 94%. The traditional Chinese medicine composition has mild medicinal properties, good safety, stable curative effect, and is not easy to relapse, and is suitable for long-term taking.

The present invention relates to a novel antisense transcript to the human SLC2A1 (Glut1) gene, variants and fragments thereof. This antisense transcript can be used to modulate Glut1 expression and serve to restore Glut1, and as a therapeutic for treating or preventing Glut 1 deficiency syndrome, or other Glut1 related conditions including certain cancers, diabetes, Alzheimer's disease, and retinitis pigmentosa.

This invention relates to the treatment of glucose transporter type 1 deficiency syndrome (Glut1-DS). In particular, the invention relates to specific medium-chain triglyceride compositions, enriched for C10 (decanoic acid), for use in treating movement disorders in Glut1-DS patients.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating post-infection irritable bowel syndrome as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10 to 15 parts of rhizoma atractylodis macrocephalae, 10 to 20 parts of radix paeoniae alba, 3 to 7 parts of pericarpium citri reticulatae, 5 to 15 parts of radix saposhnikoviae, 10 to 20 parts of folium microcotis, 10 to 20 parts of plumeria rubra, 5 to 15 parts of kapok, 25 to 35 parts of rhizoma smilacis glabrae and 5 to 15 parts of flos albiziae. Animal experiments show that the traditional Chinese medicine composition can effectively improve diarrhea phenotypes and depressive symptoms of rats with PI-IBS liver depression and spleen deficiency syndromes, relieve high sensitivity of viscera, recover a tight junction structure and a cell desmosome structure of colon, up-regulate cell TJ protein expression, recover Th1 / Th2 immune imbalance of blood, reduce the level of proinflammatory factors (TNF-alpha) in colon tissue, and improve the immunity of the rats. And the levels of LPS, DAO and D-LA in serum are up-regulated. Therefore, the traditional Chinese medicine composition disclosed by the invention can be used for effectively treating the liver depression and spleen deficiency syndrome of the irritable bowel syndrome after infection.

According to the RA traditional Chinese medicine syndrome typing based on the protein antibody chip technology and application, the protein antibody chip technology is applied to RA traditional Chinese medicine syndrome typing for the first time, and high-throughput and multi-target detection is achieved. Key markers such as IL-6R and TIMP-2 are found, and the combination of the key markers can remarkably improve the syndrome distinguishing accuracy; compared with single ELISA detection, the protein antibody chip technology can analyze 40 inflammatory factors at the same time, and the efficiency is greatly improved. In combination with bioinformatics, molecular characteristics of the damp-heat blockage syndrome and the liver and kidney deficiency syndrome are disclosed; an objective laboratory basis is provided for traditional Chinese medicine differentiation of RA, and clinical precise typing and individualized treatment are assisted.

The invention discloses a traditional Chinese medicine navel application agent for activating an abdominal cavity immune network and a preparation method thereof, through specific compatibility of 11 pungent and warm medicines (including five medicines for resolving dampness with aromatics, five medicines for warming the interior and one medicine for astringing the intestine), and in combination with a superfine grinding technology (the particle size is less than or equal to 30 microns) and a beta-cyclodextrin inclusion process, the transdermal absorption rate of the medicines is increased to 3-5 times that of common navel therapy. Animal experiments show that the preparation can increase the phagocytic rate of macrophages in the abdominal cavity of a mouse by 32.7%, the CD4 + / CD8 + ratio of T lymphocytes is recovered from 1.2 to 1.8 + / -0.2, and the slgA concentration of mucous membranes is increased by 2.3 times. Clinical observation shows that the effective rates for diarrhea, stomachache and vomiting symptoms caused by deficiency-cold of spleen and stomach of children within 24 hours respectively reach 90.2%, 85.6% and 80.4%, and liver and kidney dysfunction is not found.

The invention discloses a Tujia ear phyllostachys pubescens scraping therapy clinical curative effect evaluation system and method, and belongs to the technical field of traditional Chinese medicine clinical curative effect evaluation. The hierarchical data acquisition system is used for integrating a basic version component and a professional version component and supporting scene-based data acquisition; the Tujia medical feature extraction module is used for analyzing eruptive disease features through a lightweight CNN model and calculating liver depression and spleen deficiency syndrome integrals by combining primary and secondary disease weights; the cloud-edge collaborative architecture is used for calculating a scraping force standard deviation sigma in real time and dynamically triggering a cloud high-precision analysis and PSQI dynamic prediction model; according to the dynamic synergistic effect model, a synergistic coefficient K is calculated in a segmented mode based on the scraping force standard deviation sigma, and quantitative combined therapy synergy is achieved; and the visual interaction interface is used for generating a three-dimensional ear curative effect atlas and outputting parameter optimization suggestions. Through multi-modal data fusion and ethnic medicine feature quantification, objective and dynamic evaluation of the curative effect of chronic insomnia is realized, and the standardization level and generalizability of the scraping therapy are remarkably improved.

Use of a compound having the formulaor combinations thereof, for increasing blood ketone levels, and / or treating a disease treatable by increasing blood ketone levels, preferably wherein the disease is selected from the list consisting of: a brain energy deficiency condition, a neurological condition, migraine, memory disorder, age-related memory disorder, brain injury, stroke, amyloid lateral sclerosis, multiple sclerosis, cognitive impairment, cognitive impairment post-intensive care, age-induced cognition impairment, Alzheimer's disease, Parkinson's disease, Huntingdon's disease, inherited metabolic disorders (such as glucose transporter type 1 deficiency syndrome and pyruvate dehydrogenase complex deficiency), depression, schizophrenia, epilepsy, narcolepsy, diabetes, obesity, non-alcoholic fatty liver disease and polycystic ovary syndrome, wherein R1, R2, R3, R4, R5 and R6 are independently a long chain fatty acid having between 16 and 20 carbons.

The present application relates to a kind of traditional Chinese medicine composition for treating spleen deficiency syndrome heart failure with cognitive dysfunction, including the following weight parts of traditional Chinese medicine composition: 18-22 parts of Huangqi, 8-12 parts of Renshen, 13-17 parts of Baishu, 13-17 parts of Shanyao, 13-17 parts of Fuling, 8-12 parts of Zexie, 8-12 parts of Huangjing, 8-12 parts of Danggui, 8-12 parts of Chuanqiong, 8-12 parts of Maidong, 8-12 parts of Zhimu, 5-7 parts of Wuyi, 8-12 parts of Chenpi, 5-7 parts of Guizhi, 8-12 parts of Hongjingtian, 10-14 parts of Wujiapi and 5-7 parts of Zhigancao.The preparation method of the present application is mainly decoction and granulation.The present application is suitable for spleen deficiency syndrome, such as fatigue, chest tightness, dyspnea, edema, dizziness, palpitation, abdominal distension, poor appetite, or cold, weak or loose stool, difficult urination, dull expression, slow speech and action, and other symptoms.Specifically suitable for heart failure with cognitive dysfunction with the above symptoms.

The invention relates to the technical field of traditional Chinese medicine preparations, in particular to a traditional Chinese medicine composition for treating diabetes and a preparation method thereof. The invention provides a composition. The composition is prepared from the following traditional Chinese medicinal materials or raw material medicines based on the following traditional Chinese medicinal materials: poria cocos, lily, gordon euryale seeds, lotus seeds, Chinese wolfberry fruits, black dates (diospyros lotus) and ampelopsis grossedentata. The composition has the functions of tonifying middle-Jiao and Qi, invigorating spleen and kidney, nourishing Yin and soothing liver, clearing heat and activating blood, can be used for treating common diabetes symptoms such as deficiency of Qi and Yin, internal heat and dysphoria, thirst and hunger, polyphagia and polydipsia, deficiency of Qi and weakness and the like caused by deficiency syndromes of visceral systems such as liver, spleen and kidney, and can relieve insulin resistance. Therefore, absorption and metabolism of cells to glucose are increased to achieve the effect of reducing blood glucose, a certain curative effect on complications of diabetes mellitus is achieved, and the treatment effect is even remarkably superior to that of a blood glucose reducing medicine metformin which is commonly used in clinic for treating diabetes mellitus. And the method has very good practical significance.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for preventing and treating recurrent respiratory tract infection and a preparation method and application. The traditional Chinese medicine composition comprises the following raw materials: lonicerae flos, folium isatidis, dandelion, houttuynia cordata, astragalus membranaceus, bighead atractylodes rhizome, divaricate saposhnikovia root, ampelopsis grossedentata, pogostemon cablin, radix glehniae and pericarpium citri reticulatae. The preparation method comprises the following steps: mixing all the raw materials, adding water and decocting. The traditional Chinese medicine composition has the obvious effects of improving the immunity of the organism and resisting inflammation. Clinical curative effect observation shows that the traditional Chinese medicine composition can obviously reduce the morbidity frequency of children with recurrent respiratory tract infection (lung-spleen qi deficiency syndrome), shorten the disease course, and effectively improve the traditional Chinese medicine syndromes of the children, such as less complexion, less breath, laziness to speak, less appetite, hidrosis and the like. The compound is based on the theory of monarch, minister, assistant and guide in traditional Chinese medicine, all the components are matched with one another, and an excellent use effect is achieved. Good application prospects are realized.

The invention relates to the field of traditional Chinese medicine, in particular to a liver depression and spleen deficiency syndrome animal model evaluation method and application thereof. The invention provides an RMS-LSCRS scale tool, which is a model recording and evaluating tool specially developed for a chronic bound stress liver depression and spleen deficiency syndrome rat model. By using an RMS-LSCRS scale tool, detailed qualitative and quantitative recording can be carried out on the modeling condition of the model developed by the rat model with the chronic constraint stress liver depression and spleen deficiency syndrome, and qualitative and quantitative evaluation can be carried out on the rat model so as to judge the success condition of modeling.